Clinical Trials Directory

Trials / Completed

CompletedNCT01530243

The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms

Phase One of Study on Urinary Stent Complications and Treatment

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
104 (actual)
Sponsor
Urmia University of Medical Sciences · Academic / Other
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Not accepted

Summary

The aim of the investigators study is to evaluate whether alpha-blockers such as terazosin and anti-cholinergics such as tolterodine can be relieve the DJ-stent related symptoms.

Detailed description

Ureteral stent (US) has been as essential tool in the urologist's surgeries and is useful instruments that its indications increase due to new stent technologies and improvement of patient's comfort. US associated with discomfort complications that include lower urinary tract symptoms (LUTS) as frequency, urgency, dysuria, incomplete emptying, flanks and suprapubic's pain, incontinence, hematuria, movement of stent, infection and encrustation of stent. US related symptoms are as same as LUTS due to benign prostate hyperplasia and overactive bladder which relieve with alpha-blockers and anticholinergic. The purpose of our study is to investigate the effect of terazosin and tolterodine lonely and together in comparison of placebo on US related symptoms. The investigators study will be done prospectively. The patients who underwent indwelling Double-j stent distributed into four groups: 1)receive placebo 2)receive terazosin 2mg twice 3)receive tolterodine 2mg daily 4) receive terazosin 2mg twice and tolterodine 2mg daily. All of the patients receive prophylactic antibiotic and on demand analgesic. After entrance to study, they fulfill the International Prostatic Symptoms Score (IPSS) and Visual Analog Scale (VAS) on the before indwelling US, two weeks after indwelling US and US removal time, then the investigators will evaluate the drug's effect on US related symptoms.

Conditions

Interventions

TypeNameDescription
DRUGPlacebosame as tolterodine and terazosin dose
DRUGTerazosine2 mg BID
DRUGTolterodine2 mg daily
DRUGTolterodine + Terazosin2mg daily and 2mg BID

Timeline

Start date
2012-01-01
Primary completion
2012-08-01
Completion
2012-09-01
First posted
2012-02-09
Last updated
2015-03-02
Results posted
2015-03-02

Locations

1 site across 1 country: Iran

Source: ClinicalTrials.gov record NCT01530243. Inclusion in this directory is not an endorsement.